Research programme: amyloid-beta inhibitors - Eisai/TorreyPines Therapeutics

Drug Profile

Research programme: amyloid-beta inhibitors - Eisai/TorreyPines Therapeutics

Alternative Names: Amyloid-beta42 modulators; Aβ42 modulators; NGX-96992; Series 591 compounds

Latest Information Update: 22 Oct 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TorreyPines Therapeutics Inc
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 22 Oct 2008 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 04 Oct 2006 TorreyPines Therapeutics has merged with Axonyx to from TorreyPines Therapeutics, Inc.
  • 08 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Alzheimer's disease and cognition disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top